inclusion criteria: a research participant will be eligible to participate in this study if all of the following criteria are met: 1. adult men or women (≥ 18 years of age) 2. pcr positive sarscov-2 3. symptomatic participants must have at least 1 of the following symptoms in the inclusion: fever or self-reported fever perception in the last 24 hours, headache, sore throat, dry cough, fatigue, chest pain or choking sensation (without associating to respiratory distress), myalgia, anosmia, ageusia or gastrointestinal symptoms with up to 10 days onset. 4. participants with arterial pulse oximetry (spo2) saturation ≥ 92% in room air at inclusion. 5. participants with the following hematological and biochemical laboratory parameters obtained in the period of 7 days before d0: * hemoglobin\> 9.0 g / dl-1 * absolute neutrophil count ≥ 1000 mm-³ * platelets ≥ 100,000 mm-3 * creatinine clearance ≥ 30 ml / min-1 using the cockcroft-gault formula * alkaline phosphatase \<10 × upper limit of normal (lsn), ast (tgos) and alt (tgps) \<10 × lsn. * laboratory pregnancy test (negative β-hcg). 6. participants must understand, sign and date the voluntary informed consent form in writing at the visit prior to any specific protocol procedure. 7. participants must be able and willing to comply with study visits and procedures, as per the protocol.

inclusion criteria: a research participant will be eligible to participate in this study if all of the following criteria are met: 1. adult men or women (≥ 18 years of age) 2. pcr positive sarscov-2 3. symptomatic participants must have at least 1 of the following symptoms in the inclusion: fever or self-reported fever perception in the last 24 hours, headache, sore throat, dry cough, fatigue, chest pain or choking sensation (without associating to respiratory distress), myalgia, anosmia, ageusia or gastrointestinal symptoms with up to 10 days onset. 4. participants with arterial pulse oximetry (spo2) saturation ≥ 92% in room air at inclusion. 5. participants with the following hematological and biochemical laboratory parameters obtained in the period of 7 days before d0: * hemoglobin\> 9.0 g / dl-1 * absolute neutrophil count ≥ 1000 mm-³ * platelets ≥ 100,000 mm-3 * creatinine clearance ≥ 30 ml / min-1 using the cockcroft-gault formula * alkaline phosphatase \<10 × upper limit of normal (lsn), ast (tgos) and alt (tgps) \<10 × lsn. * laboratory pregnancy test (negative β-hcg). 6. participants must understand, sign and date the voluntary informed consent form in writing at the visit prior to any specific protocol procedure. 7. participants must be able and willing to comply with study visits and procedures, as per the protocol.

inclusion criteria: a research participant will be eligible to participate in this study if all of the following criteria are met: adult men or women (≥ 18 years of age) pcr positive sarscov-2 symptomatic participants must have at least 1 of the following symptoms in the inclusion: fever or self-reported fever perception in the last 24 hours, headache, sore throat, dry cough, fatigue, chest pain or choking sensation (without associating to respiratory distress), myalgia, anosmia, ageusia or gastrointestinal symptoms with up to 10 days onset. participants with arterial pulse oximetry (spo2) saturation ≥ 92% in room air at inclusion. participants with the following hematological and biochemical laboratory parameters obtained in the period of 7 days before d0: hemoglobin> 9.0 g / dl-1 absolute neutrophil count ≥ 1000 mm-³ platelets ≥ 100,000 mm-3 creatinine clearance ≥ 30 ml / min-1 using the cockcroft-gault formula alkaline phosphatase <10 × upper limit of normal (lsn), ast (tgos) and alt (tgps) <10 × lsn. laboratory pregnancy test (negative β-hcg). participants must understand, sign and date the voluntary informed consent form in writing at the visit prior to any specific protocol procedure. participants must be able and willing to comply with study visits and procedures, as per the protocol.

inclusion criteria: a research participant will be eligible to participate in this study if all of the following criteria are met: adult men or women (≥ 18 years of age) pcr positive sarscov-2 symptomatic participants must have at least 1 of the following symptoms in the inclusion: fever or self-reported fever perception in the last 24 hours, headache, sore throat, dry cough, fatigue, chest pain or choking sensation (without associating to respiratory distress), myalgia, anosmia, ageusia or gastrointestinal symptoms with up to 10 days onset. participants with arterial pulse oximetry (spo2) saturation ≥ 92% in room air at inclusion. participants with the following hematological and biochemical laboratory parameters obtained in the period of 7 days before d0: hemoglobin> 9.0 g / dl-1 absolute neutrophil count ≥ 1000 mm-³ platelets ≥ 100,000 mm-3 creatinine clearance ≥ 30 ml / min-1 using the cockcroft-gault formula alkaline phosphatase <10 × upper limit of normal (lsn), ast (tgos) and alt (tgps) <10 × lsn. laboratory pregnancy test (negative β-hcg). participants must understand, sign and date the voluntary informed consent form in writing at the visit prior to any specific protocol procedure. participants must be able and willing to comply with study visits and procedures, as per the protocol.

inclusion criteria: a research participant will be eligible to participate in this study if all of the following criteria are met: 1. adult men or women (≥ 18 years of age) 2. pcr positive sarscov-2 3. symptomatic participants must have at least 1 of the following symptoms in the inclusion: fever or self-reported fever perception in the last 24 hours, headache, sore throat, dry cough, fatigue, chest pain or choking sensation (without associating to respiratory distress), myalgia, anosmia, ageusia or gastrointestinal symptoms with up to 10 days onset. 4. participants with arterial pulse oximetry (spo2) saturation ≥ 92% in room air at inclusion. 5. participants with the following hematological and biochemical laboratory parameters obtained in the period of 7 days before d0: - hemoglobin> 9.0 g / dl-1 - absolute neutrophil count ≥ 1000 mm-³ - platelets ≥ 100,000 mm-3 - creatinine clearance ≥ 30 ml / min-1 using the cockcroft-gault formula - alkaline phosphatase <10 × upper limit of normal (lsn), ast (tgos) and alt (tgps) <10 × lsn. - laboratory pregnancy test (negative β-hcg). 6. participants must understand, sign and date the voluntary informed consent form in writing at the visit prior to any specific protocol procedure. 7. participants must be able and willing to comply with study visits and procedures, as per the protocol.

inclusion criteria: a research participant will be eligible to participate in this study if all of the following criteria are met: 1. adult men or women (≥ 18 years of age) 2. pcr positive sarscov-2 3. symptomatic participants must have at least 1 of the following symptoms in the inclusion: fever or self-reported fever perception in the last 24 hours, headache, sore throat, dry cough, fatigue, chest pain or choking sensation (without associating to respiratory distress), myalgia, anosmia, ageusia or gastrointestinal symptoms with up to 10 days onset. 4. participants with arterial pulse oximetry (spo2) saturation ≥ 92% in room air at inclusion. 5. participants with the following hematological and biochemical laboratory parameters obtained in the period of 7 days before d0: - hemoglobin> 9.0 g / dl-1 - absolute neutrophil count ≥ 1000 mm-³ - platelets ≥ 100,000 mm-3 - creatinine clearance ≥ 30 ml / min-1 using the cockcroft-gault formula - alkaline phosphatase <10 × upper limit of normal (lsn), ast (tgos) and alt (tgps) <10 × lsn. - laboratory pregnancy test (negative β-hcg). 6. participants must understand, sign and date the voluntary informed consent form in writing at the visit prior to any specific protocol procedure. 7. participants must be able and willing to comply with study visits and procedures, as per the protocol.